Developer docs
API playgroundTry for free, no card

Search company profiles

Delix Therapeutics

Full company profile

uuid00007ck

Namestring
Delix Therapeutics
Legal namestring
Delix Therapeutics, Inc.
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Delix Therapeutics is a clinical-stage biotechnology company founded in 2019 and headquartered in Concord, Massachusetts, that is developing a novel class of therapeutics called neuroplastogens — compounds designed to promote neuroplasticity and rewire precise neural circuits without producing the hallucinogenic or dissociative effects associated with classical psychedelics. The company's core technology is the Neuroplastogen Engine, a discovery platform that has produced a proprietary library of more than 1,500 compounds built on more than 10 unique chemical scaffolds, targeting neuropsychiatric conditions such as major depressive disorder, PTSD, anxiety, and substance use disorders, as well as neurodegenerative indications and cochlear synaptopathy (hidden hearing loss). Its lead clinical asset, DLX-001 (zalsupindole), has progressed through Phase 1 trials in major depressive disorder; in October 2025 the FDA cleared a Phase II trial design allowing at-home administration, a first for this therapeutic class.

The company is pre-revenue and currently monetizes only through non-dilutive grants (U.S. Department of Defense, NIH/NIDA) and equity capital. Delix has raised approximately $143 million+ cumulatively across a 2020 seed, a 2021 $70M Series A led by Artis Ventures, RA Capital Management, and OMX Ventures, a 2022 $30M convertible note and $10M Comerica credit facility, and a 2025 $25M round led by UC Davis Health Ventures. Its go-to-market model is traditional pharmaceutical commercialization — distributing through pharmacies, hospitals, and healthcare providers following FDA approval — with co-development and technology partnerships (Cellectricon, Expressive Neuroscience, Cumulus Neuroscience) supporting discovery and clinical operations. The customer base is split between two end-patient segments (treatment-resistant psychiatric patients and hearing-loss patients) and a smaller research/grant segment (U.S. DoD, NIH).

Short descriptiontext

Delix Therapeutics is a clinical-stage biotech developing non-hallucinogenic neuroplastogens — a proprietary class of neuroplasticity-promoting compounds — to treat neuropsychiatric conditions such as major depressive disorder, PTSD, anxiety, and hearing loss, with lead candidate DLX-001 (zalsupindole) in FDA-cleared Phase II development.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neuroplastogen drug discovery, neuropsychiatric therapeutics development, non-hallucinogenic psychoplastogens, central nervous system drug pipeline, neuroplasticity-promoting compounds
Industry1 code
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Neuropsychiatric Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Drug Development
TypeOne Time License
Description

Delix is a clinical-stage biotech company developing neuroplastogen therapeutics. The company is pre-revenue, focused on advancing compounds through clinical trials toward FDA approval for commercialization.

delixtherapeutics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Delix Therapeutics is a clinical-stage biopharmaceutical company developing non-hallucinogenic neuroplastogens — a proprietary class of small molecules that promote neuroplasticity and rewire precise neural circuits to treat neuropsychiatric and neurodegenerative conditions. Its lead candidate DLX-001 (zalsupindole) is being advanced through Phase II clinical trials for major depressive disorder, with additional pipeline assets targeting PTSD, anxiety, substance use disorders, and hearing loss.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 12-point symptom reduction lasting four weeks post-treatment
+2 more records
Product overview1 text field

Delix Therapeutics is developing a portfolio of neuroplastogens — novel compounds that promote neuroplasticity and deliver therapeutic benefits without hallucinogenic effects. The company's Neuroplastogen Engine discovery platform has generated more than 1500 compounds based on more than 10 unique chemical scaffolds. Lead candidate DLX-001 (zalsupindole) is in Phase II development for Major Depressive Disorder, with at-home administration approved by FDA. Additional candidates include DLX-7. The pipeline targets neuropsychiatric conditions including depression, PTSD, anxiety, substance use disorders, and hearing loss.

Product and service2 records
1DLX-001 (Zalsupindole)
CategoryLead Drug Candidate — Neuropsychiatric Therapeutics
Description

A non-hallucinogenic neuroplastogen lead drug candidate in clinical development for major depressive disorder. Demonstrated rapid and sustained symptom improvement (12-point reduction lasting four weeks post-treatment) without hallucinatory, dissociative, or psychotomimetic effects, with FDA clearance for at-home oral administration in the Phase II program.

2DLX-7
CategoryDrug Candidate — Neuropsychiatric Therapeutics
Description

A lead neuroplastogen drug candidate from Delix's pipeline undergoing safety and toxicology studies as part of the company's portfolio of non-hallucinogenic psychoplastogen analogs.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership announced February 2023 to accelerate drug discovery and translatability through collaboration on discovery platforms.

2Expressive Neuroscience
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership announced February 2023 to accelerate drug discovery and translatability through neuroscience research collaboration.

delixtherapeutics.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage psychedelic-derived therapeutics company developing psilocybin therapy for treatment-resistant depression. Direct peer as both target overlapping neuropsychiatric indications through neuroplastogen-like mechanisms, but Delix's key differentiator is its non-hallucinogenic profile versus Compass's hallucinogenic approach.

2MindMed
TypeDirect peer
Description

Clinical-stage neuroscience company developing psychedelic-inspired therapies (LSD, MDMA analogs) for anxiety, ADHD, and substance use disorders. Direct peer targeting the same neuropsychiatric conditions through neuroplastogen mechanisms, though primarily with hallucinogenic compounds requiring in-clinic administration.

TypeDirect peer
Description

Clinical-stage biotech developing mebufotenin and other psychedelic-based therapies for treatment-resistant depression. Direct peer in the psychedelic-neuroplastogen space competing for similar patient populations and physician adoption.

TypeDirect peer
Description

Clinical-stage psychedelic therapeutics company developing deuterated psilocybin analogs for MDD and other psychiatric indications. Direct peer pursuing next-generation psychedelic-derived neuroplastogens with improved pharmacokinetic profiles.

5atai Life Sciences
TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing psychedelic and complementary therapies for mental health conditions, holding multiple platform investments including Compass Pathways. Direct peer addressing the same neuropsychiatric treatment-resistant populations through neuroplastogen mechanisms.

TypeDirect peer
Description

Commercial-stage CNS biopharma company that developed Zurzuvae (zuranolone) for postpartum depression and prior MDD programs. Direct peer demonstrating both the regulatory pathway and commercial challenges in CNS depression therapeutics, with comparable neuroplasticity mechanism of action.

TypeEmerging player
Description

Clinical-stage neuroscience company developing precision medicines for brain diseases including depression and other neuropsychiatric conditions. Comparable emerging peer pursuing novel CNS mechanisms with similar capital-intensive development profile.

TypeBroad incumbent
Description

Now part of Bristol Myers Squibb following 2024 acquisition, developed xanomeline-trospium (Cobenfy) for schizophrenia. Comparable CNS therapeutics developer demonstrating successful exit pathway for novel-mechanism neuropsychiatric drugs.

TypeEmerging player
Description

Clinical-stage neuroscience company developing therapeutics for CNS conditions including schizophrenia and Alzheimer's disease psychosis. Comparable emerging peer with similar funding profile targeting neuropsychiatric indications through novel mechanisms.

TypeEmerging player
Description

Clinical-stage CNS-focused company developing therapies for neurological and psychiatric disorders including depression and epilepsy. Comparable emerging peer with similar stage, indication overlap, and platform-based approach to CNS drug development.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors33 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Delix Therapeutics

Neuropsychiatric Therapeuticsdelixtherapeutics.com

Delix Therapeutics is a clinical-stage biotech developing non-hallucinogenic neuroplastogens — a proprietary class of neuroplasticity-promoting compounds — to treat neuropsychiatric conditions such as major depressive disorder, PTSD, anxiety, and hearing loss, with lead candidate DLX-001 (zalsupindole) in FDA-cleared Phase II development.

What Delix Therapeutics does

Delix Therapeutics is a clinical-stage biotechnology company founded in 2019 and headquartered in Concord, Massachusetts, that is developing a novel class of therapeutics called neuroplastogens — compounds designed to promote neuroplasticity and rewire precise neural circuits without producing the hallucinogenic or dissociative effects associated with classical psychedelics. The company's core technology is the Neuroplastogen Engine, a discovery platform that has produced a proprietary library of more than 1,500 compounds built on more than 10 unique chemical scaffolds, targeting neuropsychiatric conditions such as major depressive disorder, PTSD, anxiety, and substance use disorders, as well as neurodegenerative indications and cochlear synaptopathy (hidden hearing loss). Its lead clinical asset, DLX-001 (zalsupindole), has progressed through Phase 1 trials in major depressive disorder; in October 2025 the FDA cleared a Phase II trial design allowing at-home administration, a first for this therapeutic class.

The company is pre-revenue and currently monetizes only through non-dilutive grants (U.S. Department of Defense, NIH/NIDA) and equity capital. Delix has raised approximately $143 million+ cumulatively across a 2020 seed, a 2021 $70M Series A led by Artis Ventures, RA Capital Management, and OMX Ventures, a 2022 $30M convertible note and $10M Comerica credit facility, and a 2025 $25M round led by UC Davis Health Ventures. Its go-to-market model is traditional pharmaceutical commercialization — distributing through pharmacies, hospitals, and healthcare providers following FDA approval — with co-development and technology partnerships (Cellectricon, Expressive Neuroscience, Cumulus Neuroscience) supporting discovery and clinical operations. The customer base is split between two end-patient segments (treatment-resistant psychiatric patients and hearing-loss patients) and a smaller research/grant segment (U.S. DoD, NIH).

Delix Therapeutics firmographics

Firmographics
Name
Delix Therapeutics
Legal name
Delix Therapeutics, Inc.
Website
https://delixtherapeutics.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Delix Therapeutics is a clinical-stage biotech developing non-hallucinogenic neuroplastogens — a proprietary class of neuroplasticity-promoting compounds — to treat neuropsychiatric conditions such as major depressive disorder, PTSD, anxiety, and hearing loss, with lead candidate DLX-001 (zalsupindole) in FDA-cleared Phase II development.
Ownership category
akta.pro rank

Delix Therapeutics industry classification

Industry
Product category
Neuropsychiatric Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Neuroplastogen drug discovery
  • Neuropsychiatric therapeutics development
  • Non-hallucinogenic psychoplastogens
  • Central nervous system drug pipeline
  • Neuroplasticity-promoting compounds

Where Delix Therapeutics is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Delix Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Drug Development: Delix is a clinical-stage biotech company developing neuroplastogen therapeutics. The company is pre-revenue, focused on advancing compounds through clinical trials toward FDA approval for commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Delix Therapeutics product offering

Product offering

Core offering

Delix Therapeutics is a clinical-stage biopharmaceutical company developing non-hallucinogenic neuroplastogens — a proprietary class of small molecules that promote neuroplasticity and rewire precise neural circuits to treat neuropsychiatric and neurodegenerative conditions. Its lead candidate DLX-001 (zalsupindole) is being advanced through Phase II clinical trials for major depressive disorder, with additional pipeline assets targeting PTSD, anxiety, substance use disorders, and hearing loss.

Product overview

Delix Therapeutics is developing a portfolio of neuroplastogens — novel compounds that promote neuroplasticity and deliver therapeutic benefits without hallucinogenic effects. The company's Neuroplastogen Engine discovery platform has generated more than 1500 compounds based on more than 10 unique chemical scaffolds. Lead candidate DLX-001 (zalsupindole) is in Phase II development for Major Depressive Disorder, with at-home administration approved by FDA. Additional candidates include DLX-7. The pipeline targets neuropsychiatric conditions including depression, PTSD, anxiety, substance use disorders, and hearing loss.

Differentiator

Problem solved

Functional benefit

Products and services

  • DLX-001 (Zalsupindole) A non-hallucinogenic neuroplastogen lead drug candidate in clinical development for major depressive disorder. Demonstrated rapid and sustained symptom improvement (12-point reduction lasting four weeks post-treatment) without hallucinatory, dissociative, or psychotomimetic effects, with FDA clearance for at-home oral administration in the Phase II program.
  • DLX-7 A lead neuroplastogen drug candidate from Delix's pipeline undergoing safety and toxicology studies as part of the company's portfolio of non-hallucinogenic psychoplastogen analogs.

Quantifiable outcome

  • 12-point symptom reduction lasting four weeks post-treatment
  • +2 more outcomes

Companies that use Delix Therapeutics

Customer profile

Segments2 records

Ideal customer profiles1 record

Delix Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Delix Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor.

  • CellectriconminorStrategic or Co-development PartnerPartnership announced February 2023 to accelerate drug discovery and translatability through collaboration on discovery platforms.
  • Expressive NeuroscienceminorStrategic or Co-development PartnerPartnership announced February 2023 to accelerate drug discovery and translatability through neuroscience research collaboration.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Delix Therapeutics competitors and assessment

Company assessment

Direct peers

  • Compass Pathways: Clinical-stage psychedelic-derived therapeutics company developing psilocybin therapy for treatment-resistant depression. Direct peer as both target overlapping neuropsychiatric indications through neuroplastogen-like mechanisms, but Delix's key differentiator is its non-hallucinogenic profile versus Compass's hallucinogenic approach.
  • MindMed: Clinical-stage neuroscience company developing psychedelic-inspired therapies (LSD, MDMA analogs) for anxiety, ADHD, and substance use disorders. Direct peer targeting the same neuropsychiatric conditions through neuroplastogen mechanisms, though primarily with hallucinogenic compounds requiring in-clinic administration.
  • GH Research: Clinical-stage biotech developing mebufotenin and other psychedelic-based therapies for treatment-resistant depression. Direct peer in the psychedelic-neuroplastogen space competing for similar patient populations and physician adoption.
  • Cybin: Clinical-stage psychedelic therapeutics company developing deuterated psilocybin analogs for MDD and other psychiatric indications. Direct peer pursuing next-generation psychedelic-derived neuroplastogens with improved pharmacokinetic profiles.
  • atai Life Sciences: Clinical-stage biopharmaceutical company developing psychedelic and complementary therapies for mental health conditions, holding multiple platform investments including Compass Pathways. Direct peer addressing the same neuropsychiatric treatment-resistant populations through neuroplastogen mechanisms.
  • Sage Therapeutics: Commercial-stage CNS biopharma company that developed Zurzuvae (zuranolone) for postpartum depression and prior MDD programs. Direct peer demonstrating both the regulatory pathway and commercial challenges in CNS depression therapeutics, with comparable neuroplasticity mechanism of action.

Emerging players

  • Neumora Therapeutics: Clinical-stage neuroscience company developing precision medicines for brain diseases including depression and other neuropsychiatric conditions. Comparable emerging peer pursuing novel CNS mechanisms with similar capital-intensive development profile.
  • MapLight Therapeutics: Clinical-stage neuroscience company developing therapeutics for CNS conditions including schizophrenia and Alzheimer's disease psychosis. Comparable emerging peer with similar funding profile targeting neuropsychiatric indications through novel mechanisms.
  • Praxis Precision Medicines: Clinical-stage CNS-focused company developing therapies for neurological and psychiatric disorders including depression and epilepsy. Comparable emerging peer with similar stage, indication overlap, and platform-based approach to CNS drug development.

Broad incumbents

  • Karuna Therapeutics: Now part of Bristol Myers Squibb following 2024 acquisition, developed xanomeline-trospium (Cobenfy) for schizophrenia. Comparable CNS therapeutics developer demonstrating successful exit pathway for novel-mechanism neuropsychiatric drugs.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Delix Therapeutics social profiles

Digital presence

Delix Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Delix Therapeutics leadership team

Management profile

Number of profiles

Profiles5 records

Delix Therapeutics funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors33 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Delix Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Delix Therapeutics

What does Delix Therapeutics do?

Delix Therapeutics is a clinical-stage biopharmaceutical company developing non-hallucinogenic neuroplastogens — a proprietary class of small molecules that promote neuroplasticity and rewire precise neural circuits to treat neuropsychiatric and neurodegenerative conditions. Its lead candidate DLX-001 (zalsupindole) is being advanced through Phase II clinical trials for major depressive disorder, with additional pipeline assets targeting PTSD, anxiety, substance use disorders, and hearing loss.

Is Delix Therapeutics a public or private company?

Delix Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Delix Therapeutics founded?

Delix Therapeutics was founded in 2019. It employs 11 to 50 people.

Where is Delix Therapeutics based?

Delix Therapeutics is headquartered in Boston, United States, in the North America region.

How does Delix Therapeutics make money?

One revenue line is on record: pharmaceutical Drug Development.

Who are Delix Therapeutics's main competitors?

Direct peers on record are Compass Pathways, MindMed, GH Research, Cybin, atai Life Sciences and Sage Therapeutics. Emerging players are Neumora Therapeutics, MapLight Therapeutics and Praxis Precision Medicines. Karuna Therapeutics is listed as a broad incumbent.

Does Delix Therapeutics have an API?

No public API is recorded for Delix Therapeutics.

What industry is Delix Therapeutics in?

Delix Therapeutics's product category is Neuropsychiatric Therapeutics. Its primary akta.pro industry code is HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceDelix raises $100M to advance at-home psychedelic without hallucinogenic effectsDelix Therapeutics closed a $100 million Series C round led by Johnson & Johnson to advance its investigational psychedelic zalsupindole for depression. The oral drug, designed to avoid hallucinogenic effects, is slated for at-home Phase 2 testing in the first half of 2027. Proceeds will also fund its broader neuroplastogen pipeline.citybizDelix Closes $100M Series C to Push Treatment of Psychiatric DisordersDelix Therapeutics closed a $100 million Series C led by Johnson & Johnson and SV Health Investors. The funding will advance Zalsupindole, a neuroplastogen, through Phase II, with Phase 1b showing a 50% mean reduction in depression scores. Phase II is expected in the first half of 2027.Pharmaceutical TechnologyDelix Therapeutics raises $100m for Zalsupindole developmentDelix Therapeutics raised $100M in a Series C round to fund zalsupindole (DLX001) development. The company will advance the neuroplastogen into Phase II, with a placebo-controlled trial planned for early 2027. Proceeds will also expand its neurodegeneration pipeline.MarketScreenerJ&J Venture Arm Invests as Delix Therapeutics Raises $100 MillionJohnson & Johnson's venture capital arm invested in Delix Therapeutics, which is developing psychedelic compounds without hallucinatory effects. The company raised $100 million in a Series C led by J&J Innovation, JJDC, and SV Health Investors' Dementia Discovery Fund. Delix expects to initiate a Phase II trial in the first half of 2027.MarketWatchJ&J Venture Arm Invests as Delix Therapeutics Raises $100MDelix Therapeutics raised $100 million in a Series C financing led by Johnson & Johnson's venture arm, J&J Innovation, and SV Health Investors' Dementia Discovery Fund. The funds will advance Zalsupindole through Phase IIb proof of concept in recurrent major depressive disorder and support its neuroplastogen pipeline. Delix expects to initiate a Phase II trial in the first half of 2027.Seeking AlphaJ&J gets into psychedelic treatments with backing of Delix Therapeutics (JNJ:NYSE)Johnson & Johnson's venture capital fund JJDC is backing a $100M financing round for Delix Therapeutics, which develops psychedelic-based treatments for neurological disorders. The funds will support phase II trials, with J&J's involvement signaling interest in the psychedelic space.Endpoints NewsDelix raises $100M round to advance pipeline of psychedelics without the tripDelix Therapeutics raised $100 million in a Series C round to advance its pipeline of psychedelics without the trip. The funding aims to catch up to a growing group of psychedelics and neuroplastogen drugmakers.FinSMEsDelix Therapeutics Raises $100M in Series C FundingDelix Therapeutics raised $100M in Series C funding led by Johnson & Johnson and SV Health Investors' Dementia Discovery Fund. The company will use the funds to advance Zalsupindole through Phase IIb in recurrent major depressive disorder and expand its neuroplastogen pipeline into clinical stages.Startup ResearcherDelix Therapeutics Raises US$100 Million Series CDelix Therapeutics raised $100 million in an oversubscribed Series C led by JJDC and SV Health Investors. The capital will fund Phase IIb proof-of-concept testing for Zalsupindole in recurrent major depressive disorder, with a trial expected in the first half of 2027.Business Wire BlogDelix Therapeutics Closes Oversubscribed $100 Million Series C Financing to Advance Zalsupindole Into Phase II Development and Finance Broader Pipeline Advancement/ExpansionDelix Therapeutics closed an oversubscribed $100 million Series C financing led by Johnson & Johnson and SV Health Investors. The funds will advance Zalsupindole into Phase IIb proof-of-concept in major depressive disorder, with the trial expected to start in the first half of 2027.